Literature DB >> 16710076

Hormone profiles after intramuscular injection of testosterone enanthate in patients with hypogonadism.

Ryuto Nakazawa1, Katsuyuki Baba, Masaru Nakano, Takuyuki Katabami, Nobuhiko Saito, Takesi Takahashi, Teruaki Iwamoto.   

Abstract

To examine hormone levels after androgen replacement therapy (ART) in Japanese male patients with hypogonadism, nine Japanese male patients with hypogonadism (serum total testosterone (tT) or free testosterone (fT) levels of < or = 2.7 ng/mL or < or = 10 pg/mL, respectively; average age, 59 years) were enrolled. They were treated with 125 mg of testosterone enanthate by single intramuscular injection. Blood samples were collected on the morning of the day of treatment, pre-ART, as well as on days 1 to 7 and day 14 after administration. Serum levels of tT, fT, estradiol (E2), follicle-stimulating hormone (FSH), luteinizing hormone (LH), and sex hormone-binding globulin (SHBG) were determined. On day 1 after administration, the mean serum levels of tT and fT were 7.62 ng/mL and 23.22 pg/mL, respectively. Serum levels of tT and fT on day 14 after administration were lower than their pre-ART values. One patient exhibited abnormally high serum tT and fT levels of 19.6 ng/mL and 44.4 pg/mL, respectively. Serum levels of LH and FSH began to decrease gradually on day 5 after administration. Serum levels of SHBG did not change throughout the observation period. Serum levels of E2 increased 1.7 times on day 1 after administration but returned to its pre-ART value by day 14 after administration. The dose of testosterone enanthate for male patients with hypogonadism requiring ART should be determined carefully because some patients exhibited high serum levels of androgen beyond the physiological range and gonadotropin was suppressed in all treated patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16710076     DOI: 10.1507/endocrj.k05-069

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  4 in total

1.  Urinary and serum hormones profiles after testosterone enanthate administration in male hypogonadism: concerns on the detection of doping with testosterone in treated hypogonadal athletes.

Authors:  L Di Luigi; P Sgrò; F Romanelli; M Mazzarino; F Donati; M C Braganò; S Bianchini; V Fierro; M Casasco; F Botrè; A Lenzi
Journal:  J Endocrinol Invest       Date:  2009-03-24       Impact factor: 4.256

2.  Effect of a single injection of testosterone enanthate on 17β estradiol and bone turnover markers in hypogonadal male patients.

Authors:  V Camozzi; G Bonanni; A Frigo; M Piccolo; S Ferasin; M Zaninotto; M Boscaro; G Luisetto
Journal:  J Endocrinol Invest       Date:  2014-10-16       Impact factor: 4.256

3.  Leydig cell transplantation restores androgen production in surgically castrated prepubertal rats.

Authors:  Jie Sun; Ye-Bin Xi; Zhong-De Zhang; Ping Shen; Huai-Yuan Li; Min-Zhi Yin; Wei-Yi Li; Cheng-Ren Shi
Journal:  Asian J Androl       Date:  2009-05-18       Impact factor: 3.285

4.  Testosterone Replacement Therapy in Chronic Kidney Disease Patients.

Authors:  Ryszard Skiba; Aleksandra Rymarz; Anna Matyjek; Jolanta Dymus; Agnieszka Woźniak-Kosek; Tomasz Syryło; Henryk Zieliński; Stanisław Niemczyk
Journal:  Nutrients       Date:  2022-08-22       Impact factor: 6.706

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.